Table 4. Summary of adverse events reported by ≥2 subjects in any treatment group (safety population).

Adverse event, n (%)	Placebo(n = 14)	CDP323 100 mg bid (n = 14)	CDP323 500 mg bid (n = 15)	CDP323 1000 mg qd (n = 14)	CDP323 1000 mg bid (n = 14)
Subjects with at least one AE	13 (92.9)	7 (50.0)	13 (86.7)	10 (71.4)	13 (92.9)
Headache	3 (21.4)	2 (14.3)	0	3 (21.4)	5 (35.7)
Fatigue	3 (21.4)	0	3 (20.0)	1 (7.1)	4 (28.6)
Diarrhea	3 (21.4)	0	2 (13.3)	1 (7.1)	0
Hypoasthesia	1 (7.1)	0	1 (6.7)	1 (7.1)	2 (14.3)
Muscle spasms	1 (7.1)	1 (7.1)	1 (6.7)	0	2 (14.3)
Vomiting	2 (14.3)	0	1 (6.7)	0	2 (14.3)
Back pain	0	0	1 (6.7)	2 (14.3)	1 (7.1)
Palpitations	0	3 (21.4)	1 (6.7)	0	0
Paresthesia	2 (14.3)	0	2 (13.3)	0	0
Muscular weakness	0	0	0	1 (7.1)	2 (14.3)
Dysphonia	0	0	0	2 (14.3)	0
Fall	0	0	0	0	2 (14.3)
Herpes simplex	0	0	2 (13.3)	0	0
Pain in extremity	0	0	2 (13.3)	0	0
Pharyngolarungeal pain	0	0	0	0	2 (14.3)

AE = adverse event; bid = twice daily; qd = once daily.